Completed OBSERVATIONAL NCT02607371

Anticoagulation Preference by AF Patients Study (PRiSMA-AF)

AF Patient Preferences Towards NOAC Versus VKA Treatment: a Patient Preference Study

Sponsor: Bayer

Interventions Apixaban Dabigatran-etexilate Edoxaban NOACs including Rivaroxaban (Xarelto, BAY59-7939) VKAs

Updated 7 times since 2017 Last updated: Sep 13, 2017 Started: Aug 27, 2015 Primary completion: Oct 15, 2016 Completion: Oct 15, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02607371, this observational or N/A phase trial focuses on Atrial Fibrillation and remains completed. Sponsored by Bayer, it has been updated 7 times since 2015, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 2 earlier versions

Oct 2017 — Apr 2018 [monthly]

Completed NA

Phase: PHASE4 → NA
Jan 2017 — Oct 2017 [monthly]

Completed PHASE4

First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Many Locations, Switzerland